Business Description
Stenocare AS
ISIN : DK0061078425
Total Employee Number:
4Compare
Compare
Traded in other countries / regions
STENO.DenmarkS7C.Germany IPO Date
2020-07-02Description
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.43 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | 7.43 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 10.81 | |||||
Beneish M-Score | 35.36 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.2 | |||||
3-Year EBITDA Growth Rate | 58.1 | |||||
3-Year EPS without NRI Growth Rate | 56 | |||||
3-Year FCF Growth Rate | 36 | |||||
3-Year Book Growth Rate | -41.9 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 25.39 | |||||
9-Day RSI | 35.06 | |||||
14-Day RSI | 39.57 | |||||
3-1 Month Momentum % | -1.04 | |||||
6-1 Month Momentum % | -32.78 | |||||
12-1 Month Momentum % | 95.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.63 | |||||
Quick Ratio | 1.18 | |||||
Cash Ratio | 0.23 | |||||
Days Sales Outstanding | 69.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -25.9 | |||||
Shareholder Yield % | 5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -3.25 | |||||
Net Margin % | -9.25 | |||||
EBITDA Margin % | 2.22 | |||||
FCF Margin % | -41.6 | |||||
OCF Margin % | -41.6 | |||||
ROE % | -16.84 | |||||
ROA % | -8.35 | |||||
ROIC % | -4.92 | |||||
3-Year ROIIC % | -61.41 | |||||
ROC (Joel Greenblatt) % | -22.72 | |||||
ROCE % | -4.28 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.4 | |||||
PB Ratio | 4.77 | |||||
Price-to-Tangible-Book | 12.5 | |||||
EV-to-EBIT | -179.13 | |||||
EV-to-EBITDA | 214.96 | |||||
EV-to-Revenue | 4.77 | |||||
EV-to-FCF | -11.67 | |||||
Price-to-GF-Value | 0.43 | |||||
| Price-to-Net-Current-Asset-Value | 12.5 | |||||
Earnings Yield (Greenblatt) % | -0.55 | |||||
FCF Yield % | -8.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Stenocare AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.238 | ||
| EPS (TTM) (€) | -0.001 | ||
| Beta | 2.1252 | ||
| 3-Year Sharpe Ratio | 0.13 | ||
| 3-Year Sortino Ratio | 0.27 | ||
| Volatility % | 110.68 | ||
| 14-Day RSI | 39.57 | ||
| 14-Day ATR (€) | 0.004421 | ||
| 20-Day SMA (€) | 0.130275 | ||
| 12-1 Month Momentum % | 95.74 | ||
| 52-Week Range (€) | 0.0736 - 0.346 | ||
| Shares Outstanding (Mil) | 43.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Stenocare AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Stenocare AS Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 | In 41 days | ||
| First quarter earnings results for 2026 | 2026-05-07 | 0.19 (+3.02%) | ||
| General meeting for 2025 | 2026-04-29 10:30 | 0.14 (+0.75%) | ||
| Annual report for 2025 | 2026-03-26 | 0.11 (+0.94%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 0.18 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 0.21 (+6.50%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 0.09 (+2.25%) | ||
| General meeting for 2024 | 2025-05-15 10:00 | 0.05 (-2.40%) | ||
| First quarter earnings results for 2025 | 2025-05-08 | 0.05 (-5.39%) |
Show
Entries
Stenocare AS Frequently Asked Questions
What is Stenocare AS(FRA:S7C)'s stock price today?
The current price of FRA:S7C is €0.13. The 52 week high of FRA:S7C is €0.35 and 52 week low is €0.07.
When is next earnings date of Stenocare AS(FRA:S7C)?
The next earnings date of Stenocare AS(FRA:S7C) is 2026-08-21 Est..
Does Stenocare AS(FRA:S7C) pay dividends? If so, how much?
Stenocare AS(FRA:S7C) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Stenocare AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers